Suggestive SNP-SNP interactions—primary analysis.

<p>SNP: single nucleotide polymorphism, Chr: chromosome; MAF: minor allele frequency; BHF-FHS: British Heart Foundation Family Heart Study; MIGen: Myocardial Infarction Genetics Consortium; SNPA Pvalue: level of nominal statistical significance for single marker association with coronary artery disease for SNP A; SNPB Pvalue: level of nominal statistical significance for single marker association with coronary artery disease for SNP B; Int. Pvalue BHF-FHS: interaction P value in BHF-FHS; Int. Pvalue MIGen: interaction P value in MIGen; N/A: replication not available. PDE11A: phosphodiesterase 11A; SEC1P: secretory blood group 1, pseudogene; SERPINA12: serpin peptidase inhibitor, clade A; SRI: sorcin; ZHX2: zinc fingers and homeoboxes 2; NR5A2: nuclear receptor subfamily 5, group A, member 2; ANGPTL4: angiopoietin-like 4; NRG3: neuregulin 3; RPSAP15: ribosomal protein SA pseudogene 15; CSRP3: cysteine and glycine-rich protein 3; GSTM3: glutathione S-transferase mu 3; RYR2: ryanodine receptor 2; TBXAS1: thromboxane A synthase 1; TAC1: tachykinin, precursor 1; P2RX4: purinergic receptor P2X, ligand-gated ion channel, 4; SCARB2: scavenger receptor class B, member 2; NOD1: nucleotide-binding oligomerization domain containing 1; PDGFD: platelet derived growth factor D.</p><p>Suggestive SNP-SNP interactions—primary analysis.</p

Baseline Characteristics of cases in the British Heart Foundation-Family Heart Study and the Myocardial Infarction Genetics studies.

<p>Data are means and standard deviations or counts and percentages, BHF-FHS: British Heart Foundation Family Heart Study; MIGen: Myocardial Infarction Genetics Consortium; MI: myocardial infarction; BMI: body mass index.</p><p>Baseline Characteristics of cases in the British Heart Foundation-Family Heart Study and the Myocardial Infarction Genetics studies.</p

A schematic illustration of SNP selection process for the primary analysis.

<p>A schematic illustration of SNP selection process for the primary analysis.</p

SNP selection process for the secondary analysis.

<p>SNP selection process for the secondary analysis.</p

Regional association plots for the two associated SNPs with SCD.

<p>Each SNP is plotted with respect to its chromosomal location (x-axis) and –log₁₀P-value (y-axis on the left). The spikes indicate the recombination rate (y-axis on the right) at that region of the chromosome.</p

Summary of the two loci associated with SCD.

<p>Chr, chromosome; SE, standard error; OR, odds ratio.</p

Manhattan plot of associated findings.

<p>Data is displayed as –log₁₀P values against chromosomal location for the 119,117 SNPs that were included in the statistical analysis. The dotted line represents the conservative significance threshold of P = 4.2×10⁻⁷. The two loci that showed an association at this level are plotted in red.</p

Meta-analysis results of Mendelian randomization analyses on effect of <i>FTO</i>-derived adiposity on cardiovascular and metabolic disease: quantitative phenotypes.

a<p>Beta coefficient corresponds to one-unit increase in BMI (kg/m²).</p>b<p>Beta coefficient corresponds to per-allele change.</p>c<p>Values were transformed to natural logarithm scale prior to analysis.</p

Comparison of our study with previous Mendelian randomization studies of adiposity on cardiometabolic phenotypes.

a<p>No formal MR study, although the association of <i>FTO</i> and T2D is well known.</p><p>N.A, not applicable.</p

Meta-analysis results of Mendelian randomization analyses on effect of <i>FTO</i>-derived adiposity on cardiovascular and metabolic disease: dichotomous outcomes.

a<p>OR/HR corresponds to one-unit increase in BMI (kg/m²).</p>b<p>OR/HR corresponds to per-allele change.</p>c<p>Only one study; meta-analysis not performed.</p><p>HR, hazard ratio.</p